CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group

Marco Paulli, Emilio Berti, Renato Rosso, Emanuela Boveri, Sandra Kindl, Catherine Klersy, Mario Lazzarino, G. Borroni, Fabio Menestrina, Marco Santucci, Claudio Gambini, Gabriele Vassallo, Umberto Magrini, Wolfram Sterry, Günther Burg, Marie Louise Geerts, Chris J L M Meijer, Rein Willemze, Alfred C. Feller, Hans Konrad Müller-HermelinkMarshall E. Kadin

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Purpose: Recently, it has been shown that CD30 antigen expression is associated with a relatively favorable prognosis in primary cutaneous large-cell lymphomas (CLCLs). However, prognostic subsets within the CD30+ group have been difficult to identify due to lack of uniform clinicopathologic and immunophenotypic criteria, limited clinical information, and the inclusion of relatively few patients for statistical analysis in prior studies. To address these problems, we formed a multicentric study group of pathologists and dermatologists to classify and evaluate 92 cases of CD30+ cutaneous lymphoproliferative disorders. Patients and Methods: An expert panel established consensus diagnoses for 86 CD30+ cutaneous lymphomas. Cases, clinically and histologically classified as lymphomatoid papulosis (LyP), anaplastic large-cell lymphoma (ALCL), nonanaplastic lymphoma, and borderline histology between LyP and ALCL, were then analyzed statistically by univariate, multivariate, and Cox regression model analysis of potential prognostic features. Results: Spontaneous regression and age less than 60 years were associated with a favorable prognosis, while extracutaneous disease and age greater than 60 had a poor prognosis. Patients with LyP had the best prognosis, followed by those with primary CD30+ lymphomas, regardless of cytologic type (anaplastic or nonanaplastic). Borderline cases, morphologically indistinguishable from LyP and CD30+ ALCL, had a favorable prognosis, similar to LyP. Conclusion: Our findings indicate that CD30+ cutaneous lymphoproliferative disorders comprise a spectrum of closely related skin lesions, which can be assigned a relatively favorable or unfavorable prognosis by a combined clinical and pathologic analysis.

Original languageEnglish
Pages (from-to)1343-1354
Number of pages12
JournalJournal of Clinical Oncology
Volume13
Issue number6
Publication statusPublished - Jun 1995

Fingerprint

Lymphomatoid Papulosis
Lymphoproliferative Disorders
Skin Neoplasms
Lymphoma
Anaplastic Large-Cell Lymphoma
Skin
Research
CD30 Antigens
Therapeutics
Proportional Hazards Models
Histology
Regression Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases : A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group. / Paulli, Marco; Berti, Emilio; Rosso, Renato; Boveri, Emanuela; Kindl, Sandra; Klersy, Catherine; Lazzarino, Mario; Borroni, G.; Menestrina, Fabio; Santucci, Marco; Gambini, Claudio; Vassallo, Gabriele; Magrini, Umberto; Sterry, Wolfram; Burg, Günther; Geerts, Marie Louise; Meijer, Chris J L M; Willemze, Rein; Feller, Alfred C.; Müller-Hermelink, Hans Konrad; Kadin, Marshall E.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 06.1995, p. 1343-1354.

Research output: Contribution to journalArticle

Paulli, M, Berti, E, Rosso, R, Boveri, E, Kindl, S, Klersy, C, Lazzarino, M, Borroni, G, Menestrina, F, Santucci, M, Gambini, C, Vassallo, G, Magrini, U, Sterry, W, Burg, G, Geerts, ML, Meijer, CJLM, Willemze, R, Feller, AC, Müller-Hermelink, HK & Kadin, ME 1995, 'CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1343-1354.
Paulli, Marco ; Berti, Emilio ; Rosso, Renato ; Boveri, Emanuela ; Kindl, Sandra ; Klersy, Catherine ; Lazzarino, Mario ; Borroni, G. ; Menestrina, Fabio ; Santucci, Marco ; Gambini, Claudio ; Vassallo, Gabriele ; Magrini, Umberto ; Sterry, Wolfram ; Burg, Günther ; Geerts, Marie Louise ; Meijer, Chris J L M ; Willemze, Rein ; Feller, Alfred C. ; Müller-Hermelink, Hans Konrad ; Kadin, Marshall E. / CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases : A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1343-1354.
@article{8b0faa591b9d4538837c79903ae0d82c,
title = "CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group",
abstract = "Purpose: Recently, it has been shown that CD30 antigen expression is associated with a relatively favorable prognosis in primary cutaneous large-cell lymphomas (CLCLs). However, prognostic subsets within the CD30+ group have been difficult to identify due to lack of uniform clinicopathologic and immunophenotypic criteria, limited clinical information, and the inclusion of relatively few patients for statistical analysis in prior studies. To address these problems, we formed a multicentric study group of pathologists and dermatologists to classify and evaluate 92 cases of CD30+ cutaneous lymphoproliferative disorders. Patients and Methods: An expert panel established consensus diagnoses for 86 CD30+ cutaneous lymphomas. Cases, clinically and histologically classified as lymphomatoid papulosis (LyP), anaplastic large-cell lymphoma (ALCL), nonanaplastic lymphoma, and borderline histology between LyP and ALCL, were then analyzed statistically by univariate, multivariate, and Cox regression model analysis of potential prognostic features. Results: Spontaneous regression and age less than 60 years were associated with a favorable prognosis, while extracutaneous disease and age greater than 60 had a poor prognosis. Patients with LyP had the best prognosis, followed by those with primary CD30+ lymphomas, regardless of cytologic type (anaplastic or nonanaplastic). Borderline cases, morphologically indistinguishable from LyP and CD30+ ALCL, had a favorable prognosis, similar to LyP. Conclusion: Our findings indicate that CD30+ cutaneous lymphoproliferative disorders comprise a spectrum of closely related skin lesions, which can be assigned a relatively favorable or unfavorable prognosis by a combined clinical and pathologic analysis.",
author = "Marco Paulli and Emilio Berti and Renato Rosso and Emanuela Boveri and Sandra Kindl and Catherine Klersy and Mario Lazzarino and G. Borroni and Fabio Menestrina and Marco Santucci and Claudio Gambini and Gabriele Vassallo and Umberto Magrini and Wolfram Sterry and G{\"u}nther Burg and Geerts, {Marie Louise} and Meijer, {Chris J L M} and Rein Willemze and Feller, {Alfred C.} and M{\"u}ller-Hermelink, {Hans Konrad} and Kadin, {Marshall E.}",
year = "1995",
month = "6",
language = "English",
volume = "13",
pages = "1343--1354",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases

T2 - A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group

AU - Paulli, Marco

AU - Berti, Emilio

AU - Rosso, Renato

AU - Boveri, Emanuela

AU - Kindl, Sandra

AU - Klersy, Catherine

AU - Lazzarino, Mario

AU - Borroni, G.

AU - Menestrina, Fabio

AU - Santucci, Marco

AU - Gambini, Claudio

AU - Vassallo, Gabriele

AU - Magrini, Umberto

AU - Sterry, Wolfram

AU - Burg, Günther

AU - Geerts, Marie Louise

AU - Meijer, Chris J L M

AU - Willemze, Rein

AU - Feller, Alfred C.

AU - Müller-Hermelink, Hans Konrad

AU - Kadin, Marshall E.

PY - 1995/6

Y1 - 1995/6

N2 - Purpose: Recently, it has been shown that CD30 antigen expression is associated with a relatively favorable prognosis in primary cutaneous large-cell lymphomas (CLCLs). However, prognostic subsets within the CD30+ group have been difficult to identify due to lack of uniform clinicopathologic and immunophenotypic criteria, limited clinical information, and the inclusion of relatively few patients for statistical analysis in prior studies. To address these problems, we formed a multicentric study group of pathologists and dermatologists to classify and evaluate 92 cases of CD30+ cutaneous lymphoproliferative disorders. Patients and Methods: An expert panel established consensus diagnoses for 86 CD30+ cutaneous lymphomas. Cases, clinically and histologically classified as lymphomatoid papulosis (LyP), anaplastic large-cell lymphoma (ALCL), nonanaplastic lymphoma, and borderline histology between LyP and ALCL, were then analyzed statistically by univariate, multivariate, and Cox regression model analysis of potential prognostic features. Results: Spontaneous regression and age less than 60 years were associated with a favorable prognosis, while extracutaneous disease and age greater than 60 had a poor prognosis. Patients with LyP had the best prognosis, followed by those with primary CD30+ lymphomas, regardless of cytologic type (anaplastic or nonanaplastic). Borderline cases, morphologically indistinguishable from LyP and CD30+ ALCL, had a favorable prognosis, similar to LyP. Conclusion: Our findings indicate that CD30+ cutaneous lymphoproliferative disorders comprise a spectrum of closely related skin lesions, which can be assigned a relatively favorable or unfavorable prognosis by a combined clinical and pathologic analysis.

AB - Purpose: Recently, it has been shown that CD30 antigen expression is associated with a relatively favorable prognosis in primary cutaneous large-cell lymphomas (CLCLs). However, prognostic subsets within the CD30+ group have been difficult to identify due to lack of uniform clinicopathologic and immunophenotypic criteria, limited clinical information, and the inclusion of relatively few patients for statistical analysis in prior studies. To address these problems, we formed a multicentric study group of pathologists and dermatologists to classify and evaluate 92 cases of CD30+ cutaneous lymphoproliferative disorders. Patients and Methods: An expert panel established consensus diagnoses for 86 CD30+ cutaneous lymphomas. Cases, clinically and histologically classified as lymphomatoid papulosis (LyP), anaplastic large-cell lymphoma (ALCL), nonanaplastic lymphoma, and borderline histology between LyP and ALCL, were then analyzed statistically by univariate, multivariate, and Cox regression model analysis of potential prognostic features. Results: Spontaneous regression and age less than 60 years were associated with a favorable prognosis, while extracutaneous disease and age greater than 60 had a poor prognosis. Patients with LyP had the best prognosis, followed by those with primary CD30+ lymphomas, regardless of cytologic type (anaplastic or nonanaplastic). Borderline cases, morphologically indistinguishable from LyP and CD30+ ALCL, had a favorable prognosis, similar to LyP. Conclusion: Our findings indicate that CD30+ cutaneous lymphoproliferative disorders comprise a spectrum of closely related skin lesions, which can be assigned a relatively favorable or unfavorable prognosis by a combined clinical and pathologic analysis.

UR - http://www.scopus.com/inward/record.url?scp=0029036853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036853&partnerID=8YFLogxK

M3 - Article

C2 - 7751878

AN - SCOPUS:0029036853

VL - 13

SP - 1343

EP - 1354

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -